Evidence map›Paper›PMID 26944478›Full record

ArticleHaematologica2016

Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.

Angela Stoddart, Zhijian Qian, Anthony A Fernald, Rachel J Bergerson, Jianghong Wang, Theodore Karrison, John Anastasi, Elizabeth T Bartom, Aaron L Sarver, Megan E McNerney and 2 more

Abstract readLetter
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Signal integrator function of CXXC5 in Cancer.Cell communication and signaling : CCS · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Angela StoddartDepartment of Medicine, University of Chicago, Chicago, IL, USA astoddar@bsd.uchicago.edu.
Zhijian QianDepartment of Medicine, and University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, IL, USA.
Anthony A FernaldDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Rachel J BergersonDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Jianghong WangDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Theodore KarrisonDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
John AnastasiUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA Department of Pathology, University of Chicago, Chicago, IL, USA.
Elizabeth T BartomDepartment of Biochemistry and Molecular Genetics, Northwestern University Feinburg School of Medicine, Chicago, IL, USA.
Aaron L SarverDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Megan E McNerneyUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA Departments of Pathology and Pediatrics, and Institute for Genomics and Systems Biology, University of Chicago, Chicago, IL, USA.
David A LargaespadaDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Michelle M Le BeauDepartment of Medicine, University of Chicago, Chicago, IL, USA University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
UCCRC--ETIOLOGY OF TREATMENT-INDUCED SECONDARY LEUKEMIAP01CA040046 · NCI · UNIVERSITY OF CHICAGO · PI LE BEAU, MICHELLE M · 1985 to 2012
$19.9M
Molecular mechanisms of myeloid suppressor genes on chromosome 5R01CA190372 · NCI · UNIVERSITY OF CHICAGO · PI LE BEAU, MICHELLE M · 2015 to 2019
$1.8M
The molecular mechanism of clonal dominance in 5q(del) MDSR01DK107615 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI QIAN, ZHIJIAN · 2016 to 2019
$1.4M
Determining the role of CUX1 in myeloid neoplasiaK08CA181254 · NCI · UNIVERSITY OF CHICAGO · PI MCNERNEY, MEGAN · 2014 to 2018
$846k
Bioinformatics approaches to solve the "Missing Driver" problem in solid tumorsR50CA211249 · NCI · UNIVERSITY OF MINNESOTA · PI SARVER, AARON L · 2016 to 2020
$565k
NCI NIH HHS K08 CA181254NCI NIH HHS P01 CA040046NCI NIH HHS P30 CA014599NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA190372NCI NIH HHS R50 CA211249NIDDK NIH HHS R01 DK107615
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Intracellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteMutagenesis, InsertionalMyelodysplastic SyndromesNeoplasm ProteinsPeptide Termination FactorsProteinsRetroviridaeAnimalsDNA-Binding ProteinsMiceMice, Mutant StrainsTranscription FactorsWnt Signaling PathwayCXXC5 protein, mouseDNA-Binding ProteinsEtf1 protein, mouseIntracellular Signaling Peptides and ProteinsNeoplasm ProteinsPeptide Termination FactorsProteinsTIFAB protein, mouseTranscription Factorsdel(5q)insertional mutagenesismyeloid neoplasmsretroviralWnt pathway

Identifiers

PMID26944478
PMCPMC5013937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.